Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67%
For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off with a better offer.
For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off with a better offer.
